Drug Trial Radar · NCT05292196
A Phase II Clinical Trial of TQC3721 Suspension for Inhalation
Last checked: Nov 20, 2026Latest source record: Apr 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
59
Actual
Start
May 20, 2022
Primary completion
Jan 11, 2023
Study completion Dec 5, 2023
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TQC3721 suspension for inhalation is a PDE3/4 inhibitor developed by Chia Tai Tianqing Pharmaceutical Group Co., LTD., which can simultaneously achieve bronchial smooth muscle relaxation and anti-inflammatory effects. This is a randomized, double-blind, placebo-parallel, phase II trial of the efficacy and safety of inhaled TQC3721 suspension/placebo at different doses in patients with moderate to severe chronic obstructive pulmonary disease. Objective To evaluate the efficacy, safety and tolerability of TQC3721 inhalation suspension in the treatment of moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TQC3721 suspension for inhalationDrug
TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
TQC3721 suspension placebo for inhalationDrug
TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- The peak of Forced Expiratory Volume(FEV1)Time frame: From the enrollment of the subjects to four weeks after administration
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Gansu Provincial Hospital
Lanzhou, Gansu, China
The Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jianxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Mianyang Central Hospital
Mianyang, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.